Phenotypic and genotypic correlates of daptomycin-resistant methicillin-susceptible Staphylococcus aureus clinical isolates

다국어 초록 (Multilingual Abstract)

Daptomycin (DAP) has potent activity in vitro and in vivo against both methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA) strains.
DAP-resistance (DAP-R) in S. aureus has been mainly observed in MRSA strains, and has been linked to single nucleotide polymorphisms (SNPs) within the mprF gene leading to altered cell membrane (CM) phospholipid (PL) profiles, enhanced positive surface charge, and changes in CM fluidity. The current study was designed to delineate whether these same genotypic and phenotypic perturbations are demonstrated in clinically-derived DAP-R MSSA strains. We used three isogenic DAP-susceptible (DAP-S)/DAP-R strainpairs and compared: (i) presence of mprF SNPs, (ii) temporal expression profiles of the two key determinants (mprF and dltABCD) of net positive surface charge, (iii) increased production of mprF-dependent lysinylated-phosphatidylglycerol (L-PG), (iv) positive surface charge assays, and (v) susceptibility to cationic host defense peptides (HDPs) of neutrophil and platelet origins. Similar to prior data in MRSA, DAP-R (vs DAP-S) MSSA strains exhibited hallmark hot-spot SNPs in mprF, enhanced and dysregulated expression of both mprF and dltA, L-PG overproduction, HDP resistance and enhanced positive surface charge profiles. However, in contrast to most DAP-R MRSA strains, there were no changes in CM fluidity seen. Thus, charge repulsion via mprF- and dlt-mediated enhancement of positive surface charge may be the main mechanism to explain DAP-R in MSSA strains.

참고문헌 (Reference)

1 Ernst, C. M., "The lipid-modifying multiple peptide resistance factor is an oligomer consisting of distinct interacting synthase and flippase subunits" 6 : e02340-, 2015

2 Ernst, C., "The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion" 5 : e1000660-, 2009

3 Yang, S. J., "The Staphylococcus aureus two-component regulatory system, GraRS, senses and confers resistance to selected cationic antimicrobial peptides" 80 : 74-81, 2012

4 Peschel, A., "Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine" 193 : 1067-1076, 2001

5 Cheung, A. L., "Sitespecific mutation of the sensor kinase GraS in Staphylococcus aureus alters the adaptive response to distinct cationic antimicrobial peptides" 82 : 5336-5345, 2014

6 Yang, S. J., "Role of the LytSR two-component regulatory system in adaptation to cationic antimicrobial peptides in Staphylococcus aureus" 57 : 3875-3882, 2013

7 Yang, S. J., "Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus" 53 : 2636-2637, 2009

8 Mishra, N. N., "Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients" 206 : 1160-1167, 2012

9 Dyer, D. W., "Rapid isolation of DNA from Staphylococcus aureus" 46 : 283-285, 1983

10 Yeaman, M. R., "Platelet microbicidal protein alone and in combination with antibiotics reduces Staphylococcus aureus adherence to platelets in vitro" 62 : 3416-3423, 1994

11 Mishra, N. N., "Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains : relative roles of mprF and dlt operons" 9 : e107426-, 2014

12 Yeaman, M. R., "Partial characterization and staphylocidal activity of thrombininduced platelet microbicidal protein" 60 : 1202-1209, 1992

13 Staubitz, P., "MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important determinant in staphylococcal defensin resistance" 231 : 67-, 2004

14 Bayer, A. S., "Mechanisms of daptomycin resistance in Staphylococcus aureus : role of the cell membrane and cell wall" 1277 : 139-158, 2013

15 Kaatz, G. W., "Mechanisms of daptomycin resistance in Staphylococcus aureus" 28 : 280-287, 2006

16 Peschel, A., "Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides" 274 : 8405-8410, 1999

17 Mukhopadhyay, K., "In vitro susceptibility of Staphylococcus aureus to thrombin-induced platelet microbicidal protein-1(tPMP-1)is influenced by cell membrane phospholipid composition and asymmetry" 153 : 1187-1197, 2007

18 Bayer, A. S., "In vitro resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal protein is associated with alterations in cytoplasmic membrane fluidity" 68 : 3548-3553, 2000

19 Mishra, N. N., "In vitro crossresistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates" 55 : 4012-4018, 2011

20 Bayer, A. S., "Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates : role in cross-resistance between daptomycin and host defense antimicrobial peptides" 58 : 7462-7467, 2014

21 Friedman, L., "Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus" 50 : 2137-2145, 2006

22 Xiong, Y. Q., "Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus" 49 : 3114-3121, 2005

23 Bayer, A. S., "Frequency and distribution of single-nucleotide polymorphisms within mprF in methicillin-resistant Staphylococcus aureus clinical isolates and their role in cross-resistance to daptomycin and host defense antimicrobial peptides" 59 : 4930-4937, 2015

24 Jones, T., "Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding" 52 : 269-278, 2008

25 Yang, S. J., "Enhanced expression of dltABCD is associated with development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus" 200 : 1916-1920, 2009

26 Bayer, A. S., "Dysregulation of mprF and dltABCD expression among daptomycin-non-susceptible MRSA clinical isolates" 71 : 2100-2104, 2016

27 Mishra, N. N., "Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content" 7 : e43958-, 2012

28 Pillai, S. K., "Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF" 51 : 2223-2225, 2007

29 Murthy, M. H., "Daptomycin non-susceptible methicillin-resistant Staphylococcus aureus USA 300 isolate" 57 : 1036-1038, 2008

30 Marco, F., "Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus" 52 : 2538-2543, 2008

31 Bertsche, U., "Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation" 55 : 3922-3928, 2011

32 Cui, L., "Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus" 50 : 1079-1082, 2006

33 Yang, S. J., "Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus : evidence for multiple resistance mechanisms" 54 : 3079-3085, 2010

34 Yang, S. J., "Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance" 57 : 5658-5664, 2013

35 Mishra, N. N., "Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides" 55 : 526-531, 2011

36 Boucher, H. W., "Antimicrobial resistance : perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus" 45 : 601-608, 2007

37 Mishra, N. N., "Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus(MRSA)" 53 : 2312-2318, 2009